Welcome to our dedicated page for PPD news (Ticker: PPD), a resource for investors and traders seeking the latest updates and insights on PPD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PPD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PPD's position in the market.
PPD has secured funding from the Defense Health Agency for a five-year research project to develop drug interventions for post-traumatic stress disorder (PTSD). This project aims to test the safety and effectiveness of multiple pharmacotherapeutics for U.S. military personnel and veterans, utilizing an adaptive trial design to enhance efficiency in drug development. PPD emphasizes the urgent need for effective PTSD treatments, given the limited current options. The initiative aligns with the company's commitment to improving public health through innovative research.
PPD has earned a spot on Training magazine's Top 100 list for the 10th consecutive year, reflecting its commitment to effective employee learning and development. This recognition highlights the measurable results achieved through PPD’s training programs, which align with corporate objectives. The ranking considers various benchmarks including training budget, hours per employee, and program evaluations. Senior VP Jay Dixon emphasizes that this learning culture enhances employee engagement and customer continuity in drug development initiatives.
PPD, a global contract research organization, will host a conference call on February 24, 2021, at 9 a.m. ET to discuss its fourth quarter and full-year 2020 financial results. Investors can access the live webcast on PPD’s investor website. The call can also be dialed in at +1 877 407 0784 for U.S. participants and +1 201 689 8560 for international callers. A replay will be available after the call until March 10, 2021. PPD provides integrated drug development services and has a workforce of over 26,000 professionals across 46 countries.
PPD will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:50 p.m. ET. The presentation will feature CEO David Simmons and CFO Chris Scully. A live webcast and an archived version, along with presentation slides, will be available for 30 days via PPD's Investor Relations website.
PPD is a global contract research organization offering drug development, laboratory, and lifecycle management services, with over 25,000 professionals in 46 countries.
PPD was recognized as the Clinical Research Company of the Year at the PharmaTimes Clinical Researcher of the Year competitions. PPD's achievements include multiple awards for its clinical researchers in Clinical Research Associate and In-House CRA categories. The company also won gold in Experienced CRA and New CRA categories at the Americas event. PPD's senior VP commended the professionalism of its researchers, highlighting the importance of its training programs in achieving such accolades. The awards reflect PPD's commitment to excellence in clinical research.
PPD reported strong third quarter 2020 results, showing a revenue increase of 20.5% to $1,233.8 million and a net income growth of 95.0% to $52.0 million. The company achieved net authorizations of $1,200.3 million, a 33.3% rise year-over-year, with a backlog of $7,890.4 million—up 15.9%. Adjusted EBITDA reached $232.6 million, marking a 14.8% growth. For Q4 2020, PPD anticipates revenue between $1,256 million and $1,298 million, with adjusted EBITDA of $244 million to $250 million.
PPD, Inc. (Nasdaq: PPD) will hold a conference call on Wednesday, Oct. 28, 2020, at 9 a.m. ET to discuss its third quarter 2020 financial results. Interested parties can listen via a live webcast on PPD's investor website. The conference call will also be accessible by phone, with a replay available until Nov. 11, 2020. PPD specializes in integrated drug development and lifecycle management services for various sectors, employing over 25,000 professionals globally. This call aims to inform investors on PPD's financial performance and strategic direction.
Summary not available.
Science 37 announced the closing of an oversubscribed funding round, raising $40 million led by prominent investors including PPD and others. The funding will enhance their technology platform and global expansion to facilitate decentralized clinical trials, allowing patients to participate from home. CEO David Coman highlighted the impact of this approach on diversity in clinical research and the acceleration of drug development. This funding builds on previous investments that enhanced patient experience, recruitment capabilities, and organizational structure.